BAA research area 001 - development of vaccine candidates for biodefense and emerging infectious diseases
Active Definitive Contract Awarded Last action
- Contract number
- 75N93024C00009
- Awardee
-
Anivive Lifesciences Inc. UEI HR9KVMTD5467
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,889,710
Award facts
- Opportunity
-
- 2023 NIAID Omnibus Broad Agency Announcement Solicitation · HHSNIHNIAIDBAA20231 · Posted Jan 11, 2023
- Contract value 15% obligated
-
- $4,889,710.00 Current, with exercised options
- $33,273,522.00 Potential, with all options
- Completion date 79% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 7 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Long Beach, CA 90808, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $4,889,710 |
About this award
The National Institute of Allergy and Infectious Diseases awarded a $33.3 million definitive contract to Anivive Lifesciences Inc. for development of vaccine candidates for biodefense and emerging infectious diseases on June 7, 2024.
Anivive Lifesciences Inc. is a self-certified small disadvantaged business. The contract is priced on a cost-plus-fixed-fee basis with a ceiling value of $33,273,522 and runs through June 30, 2027. Place of performance is Long Beach, California.
The originating solicitation, posted January 11, 2023, with a due date of April 11, 2023, sought vaccine candidates capable of providing rapid and durable immunity against multiple emerging pathogens under NIAID's Broad Agency Announcement research program for biodefense and emerging infectious diseases. The awardee competed in an open market procurement without set-aside restriction.
Quick answers
Who was awarded contract 75N93024C00009?
75N93024C00009 was awarded to Anivive Lifesciences Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 7, 2024.
How much is contract 75N93024C00009 worth?
The government has obligated $4,889,710 on 75N93024C00009. Its potential value, with all options, is $33,273,522.
Was contract 75N93024C00009 competed?
The extent of competition for 75N93024C00009 was full and open competition. The government received 7 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award